Cite
HARVARD Citation
Swords, R. et al. (n.d.). KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leukemia research. pp. 123-131. [Online].